Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q4 2014 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ESSA PHARMA INC | 16 | Q3 2023 | 10.8% |
IRADIMED CORP | 16 | Q3 2023 | 5.8% |
XENON PHARMACEUTICALS INC | 15 | Q3 2023 | 2.9% |
IVERIC BIO INC | 14 | Q1 2023 | 6.5% |
SURMODICS INC | 14 | Q3 2023 | 4.7% |
NATERA INC | 13 | Q3 2023 | 3.9% |
DEXCOM INC | 13 | Q2 2023 | 4.2% |
NOVOCURE LTD | 13 | Q3 2023 | 3.4% |
CRISPR THERAPEUTICS AG | 13 | Q2 2023 | 2.6% |
LYRA THERAPEUTICS INC | 13 | Q3 2023 | 1.0% |
View Soleus Capital Management, L.P.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
13F-HR | 2021-11-15 |
View Soleus Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.